No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 20
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:20:36.270Z. Latest historical point 2025-05-08. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T13:20:36.270Z. Latest historical point 2024-04-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T13:20:36.270Z. Latest historical point 2024-08-08. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T13:20:36.270Z. Latest historical point 2024-08-08. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T13:20:36.270Z. Latest historical point 2024-05-09.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T13:20:36.270Z. Latest historical point 2024-04-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T13:20:36.270Z. Latest historical point 2024-08-08. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T13:20:36.270Z. Latest historical point 2024-08-08. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Amylyx Pharmaceuticals, Inc. (AMLX) stock was $27.78 as of Oct 5, 2026, 4:00 PM EDT, down 0.04% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +106.3% · 3-year avg +16.1%/yr
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions.
Biotechnology · Cambridge, MA
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.38
Revenue Est.
$59429.00
Last Quarter Results
EPS
$-0.39
vs Estimate
$-0.36
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1AMLX | $3.09B | $27.78 | -0.04% | +106.29% | N/A | N/A | N/A |
| 2ARQT | $3.15B | $25.15 | -0.04% | +26.11% | -0.28% | N/A | vs AMLX |
| 3DNLI | $3.16B | $19.91 | -0.45% | +28.96% | -16.91% | N/A | vs AMLX |
| 4ELVN | $3.25B | $45.47 | -3.19% | +130.94% | +24.57% | N/A | vs AMLX |
| 5DYN | $2.88B | $15.44 | +1.58% | +18.13% | -0.38% | N/A | vs AMLX |
| 6TMDX | $2.87B | $82.99 | +4.00% | -28.15% | +21.77% | N/A | vs AMLX |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 11 analysts
Average Price Target
$42.36
+52.5% upside
Low
$20.00
Current
$27.78
High
$57.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.40 | $-0.38 | $-0.35 | 6 |
| Quarter ending Dec 2026 | $-0.41 | $-0.37 | $-0.34 | 5 |
| Quarter ending Mar 2027 | $-0.37 | $-0.37 | $-0.37 | 3 |
| Quarter ending Jun 2027 | $-0.36 | $-0.36 | $-0.36 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.60 | $-1.51 | $-1.45 | 7 |
| FY 2027 | $-1.38 | $-1.18 | $-1.01 | 7 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $59429.00 | $59429.00 | $59429.00 | 11 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $24889.00 | $80625.00 | $163327.00 | 7 |
| FY 2027 | $22.18M | $56.49M | $90.77M | 7 |
